Navigation Links
Federal Trade Commission Reports: Authorized Generics, During the 180-day Exclusivity Period, Benefit Consumers and the American Healthcare System
Date:6/25/2009

- Authorized Generics Benefit Consumers and Save the American Healthcare System Money

CINCINNATI, June 25 /PRNewswire/ -- Prasco Laboratories, a Mason-based independent authorized generic company, applauds the Federal Trade Commission (FTC) for issuing their interim report on the short and long-term effects of authorized generics on competition in the prescription drug marketplace.

Prasco commends the FTC in its approach. "This Interim Report is the result of a long and arduous process in response to a 2005 request by Senators Leahy, Grassley, and Rockefeller to review the impact of the practice of authorized generics on competition during the 180-day exclusivity period," stated E. Thomas Arington, Chairman and CEO of Prasco. "The Commission's analysis supports the pro-consumer impact of the increased competition that authorized generics bring to the generic drug industry, and the resulting savings to the American consumer," stated Arington.

According to the Interim Report, the FTC found that:

  • "...[C]onsumers benefit and the healthcare system saves money during the 180-day exclusivity period when an AG enters the market..." FTC report Authorized Generics: An Interim Report - June 2009; pg. 2

  • "...[C]onsumer harm arises from the absence of AG competition against an ANDA generic, not from the presence of AG competition against an ANDA generic." FTC report Authorized Generics: An Interim Report - June 2009; pg. 4

  • "I concur in the bottom-line conclusion of the Commission's Interim Report that the Report cannot properly be read to support a legislative ban on the marketing of Authorized Generics (AGs) during the 180-day exclusivity period (or otherwise) or to suggest that AGs are harmful to consumers." Concurring statement of FTC Commissioner J. Thomas Rosch

"In 1984, Congress enacted The Drug Price Competition and Patent Term Restoration Act, commonly known as Hatch-Waxman, to encourage the development of the generics industry in order to help consumers receive lower prices on prescription drugs. The practice of authorized generics embodies the spirit in which Hatch-Waxman was created: to bring Americans, high quality low-priced pharmaceuticals. We are pleased with the FTC's conclusion, in support of making pharmaceuticals more cost-effective for American consumers," Arington concluded.

About Prasco

Prasco is the authorized generics company, whose mission is to provide both quality products and significant cost-savings to the consumer. Prasco's goal is to provide patients with the Brand-Identical experience through Prasco Authorized Generics. To find out more about Prasco Authorized Generics, visit www.prasco.com or www.authorizedgenerics.com.

websites: www.prasco.com; www.authorizedgenerics.com


'/>"/>
SOURCE Prasco
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MDMA Names New Director of Federal Affairs
2. Federal research plan to determine nanotech risks fails to deliver
3. Federal Employee Program Maintains Low Health Premiums In 2008
4. AMERIGROUP Contracts with Federal Government to Offer Medicare Advantage Health Plans in Seven States
5. SNM applauds NAS study showing need to restore federal nuclear medicine research funding
6. ACM Helps Medicaid Programs Comply With Federal Deficit Reduction Act Mandates
7. Boise(R) BEWARE(TM) Meets New Federal Guidelines Set Forth by Medicaid
8. HIV/AIDS Cases Among State and Federal Prison Inmates Fell for the Sixth Straight Year During 2005
9. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
10. Federal Trade Commission Attempts To Suppress Best-Selling Authors First Amendment Rights
11. CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: ... creation of published author, Julianne Hale, a consultant for the Intelligence Community. ... expert focusing on the Near East region. Julianne has written hundreds of ...
(Date:8/22/2017)... ... 2017 , ... Although Labor Day is not as popular for fireworks as ... displays, and numerous households celebrate the unofficial end of summer with backyard fireworks shows. ... , Kris Zambo, owner of Dynamite Fireworks in Hammond, Indiana, provides ...
(Date:8/21/2017)... ... 21, 2017 , ... FCPX LUT Monochromatic Volume 2 is an all-new Look-Up ... washed color grades to footage. A LUT is a Lookup Table that contains a ... corresponding color indicated by the table. This pack comes with 60 different monochromatic CUBE ...
(Date:8/21/2017)... ... , ... The experts have spoken. Prolonged sitting and standing are a no-no ... a healthy way these days? FlexiSpot, one of the fastest-growing manufacturers of ergonomic office ... introduce Deskcise Pro™– the world’s first sit-stand-cycle desk to backers worldwide. , The Launch ...
(Date:8/21/2017)... , ... August 21, 2017 , ... The Industrial ... Awards (IDSA IDEA®) 2017 Ceremony and Gala on Aug. 19, 2017 in Atlanta, ... of the world’s most prestigious and rigorous design competitions. See all the winners at ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)...  AOTI Inc. announced today that its fully owned ... a New York City Office in Yonkers, New York ... Wound Oxygen (TWO 2 ) homecare therapy. This new East Coast ... Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical Equipment ... Advanced Oxygen Therapy ...
(Date:8/11/2017)... CAESAREA, Israel , Aug. 11, 2017 ... company with mobile health and big data solutions, today ... results on Monday, August 14 and host a conference ... second quarter 2017 operating and financial results and its ... call will be hosted by Erez Raphael , ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
Breaking Medicine Technology: